La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Celularity Dividendo

Dividendo criteri di controllo 0/6

Celularity non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	2.0%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-US$8.93
Previsione del rendimento del dividendo a 3 anni	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

Feb 14

News Flash: Analysts Just Made A Massive Upgrade To Their Celularity Inc. (NASDAQ:CELU) Forecasts

Dec 14

Celularity: Celgene Spin-Off Developing Allogeneic Therapies

Sep 06

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di CELU siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di CELU siano aumentati.

Rendimento dei dividendi rispetto al mercato

Celularity Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di CELU rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (CELU)	n/a
Fondo del 25% del mercato (US)	1.5%
Top 25% del mercato (US)	4.4%
Media del settore (Biotechs)	2.0%
Previsione dell'analista in 3 anni (CELU)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di CELU rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di CELU rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di CELU per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché CELU non ha segnalato alcun pagamento.

Celularity Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Celularity Inc. announced delayed 10-Q filing

Celularity Inc. Revises Sales Guidance for the First Quarter of 2024

Celularity Inc. Revises Sales Guidance for the First Quarter of 2024

Celularity Presents Data of the Effect of Its T-Cell Platform on Multiple Hematological and Solid Tumors At the American Society of Clinical Oncology (Asco) Annual Meeting

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Inc. announced delayed 10-Q filing

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Celularity Inc. announced delayed annual 10-K filing

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

High number of new and inexperienced directors

Celularity Inc. Provides Sales Guidance for the First Quarter and Full Year 2024

Genting Berhad Engages in Discussions with Celularity Inc

Celularity Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Inc. announced delayed 10-Q filing

Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees

Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Celularity Inc. to Present Data from a New Product Technology in Development for Orthopedic Applications at 7th International Conference on Orthopedics

New major risk - Share price stability

Celularity Inc. Announces Results from Exploratory Analysis of Phase 1 Data Evaluating Alterations in Gene and Protein Signatures Associated with Inflammation and Fistula Formation in Patients with Crohn's Disease

Celularity Inc. announced delayed 10-Q filing

Price target decreased by 24% to US$8.63

Consensus revenue estimates decrease by 36%, EPS upgraded

Independent Director exercised options to buy US$822k worth of stock.

Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (Ctw)

Celularity Inc. Announces the Suspends of Robert Hariri as Chairman

Price target decreased by 12% to US$9.50

Celularity Inc. Announces in A Preclinical in Vivo Study of Placental Extracellular Matrix

Celularity Inc.'s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn's Disease in Phase 1, Phase 1b/2a and Phase 1b Studies

Celularity Inc. Appoints Paul Graves as Chief Communications Officer

Consensus forecasts updated

Celularity Inc. Announces Halal Certification of Its Advanced Cellular Therapeutics, Biomaterial Products and Business Model

Founder recently bought US$70k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: US$0.034 (vs US$0.47 in 3Q 2021)

Imugene’s on CARlytics Combination with Celularity’s Placental-derived off-the-shelf Allogeneic CYCART-19 T Cells Preclinical Data Presented at SITC Annual Meeting

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Celularity Promotes Two Executives in Executive Leadership Team

Celularity Appoints Adrian Kilcoyne as Executive Vice President, Chief Medical Officer and Head of Global Affairs, Patient Safety and Patient Affairs

Celularity appoints Adrian Kilcoyne as chief medical officer

Celularity Inc. Publishes New Data in Frontiers in Immunology Demonstrating Placental-Derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-Infected Cells in Vitro

Celularity Inc. Announces Resignation of Andrew L. Pecora, M.D., F.A.C.P., as Company’s President Effective as of August 31, 2022

Celularity falls after announcing fund raising deal

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Celularity falls 10% on deal for $150M common stock offering

Founder exercised options to buy US$343k worth of stock.

Price target decreased to US$10.60

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Celularity Inc. Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers

Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers

Celularity Inc. Announces the Resignation of Andrew L. Pecora as President, Effective from August 31, 2022

Price target increased to US$11.80

Celularity Inc. Announces Board Changes

Celularity Inc. Appoints Diane Parks to Board of Directors

Celularity Inc. announced that it has received $30.000007 million in funding

Consensus estimates of losses per share improve by 34%

Celularity Inc. announced that it expects to receive $30.000007 million in funding

First quarter 2022 earnings: Revenues exceed analyst expectations

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

Celularity Inc. Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

Consensus forecasts updated

Celularity Inc. Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition